BR112023016212A2 - Alfa-glucosidase ácida humana recombinante e usos da mesma - Google Patents
Alfa-glucosidase ácida humana recombinante e usos da mesmaInfo
- Publication number
- BR112023016212A2 BR112023016212A2 BR112023016212A BR112023016212A BR112023016212A2 BR 112023016212 A2 BR112023016212 A2 BR 112023016212A2 BR 112023016212 A BR112023016212 A BR 112023016212A BR 112023016212 A BR112023016212 A BR 112023016212A BR 112023016212 A2 BR112023016212 A2 BR 112023016212A2
- Authority
- BR
- Brazil
- Prior art keywords
- glucosidase
- recombinant human
- human acid
- acid alpha
- alpha
- Prior art date
Links
- 101001018026 Homo sapiens Lysosomal alpha-glucosidase Proteins 0.000 title abstract 3
- 102000045921 human GAA Human genes 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 abstract 1
- 206010053185 Glycogen storage disease type II Diseases 0.000 abstract 1
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 abstract 1
- 108010006519 Molecular Chaperones Proteins 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 201000004502 glycogen storage disease II Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01115—Branched-dextran exo-1,2-alpha-glucosidase (3.2.1.115)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
alfa-glucosidase ácida humana recombinante e usos da mesma. são providos neste documento métodos de tratamento da doença de pompe compreendendo a administração de uma população de moléculas de a-glucosidase ácida humana recombinante ou uma composição farmacêutica ou formulação da mesma, e uma chaperona farmacológica.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163148596P | 2021-02-11 | 2021-02-11 | |
| US202163162683P | 2021-03-18 | 2021-03-18 | |
| PCT/US2022/016124 WO2022174037A1 (en) | 2021-02-11 | 2022-02-11 | Recombinant human acid alpha-glucosidase and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023016212A2 true BR112023016212A2 (pt) | 2023-11-28 |
Family
ID=82837922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023016212A BR112023016212A2 (pt) | 2021-02-11 | 2022-02-11 | Alfa-glucosidase ácida humana recombinante e usos da mesma |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4291225A1 (pt) |
| JP (1) | JP2024506346A (pt) |
| KR (1) | KR20230155622A (pt) |
| AU (1) | AU2022218792A1 (pt) |
| BR (1) | BR112023016212A2 (pt) |
| CA (1) | CA3207917A1 (pt) |
| IL (1) | IL305103A (pt) |
| TW (1) | TW202245830A (pt) |
| WO (1) | WO2022174037A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023215865A1 (en) * | 2022-05-05 | 2023-11-09 | Amicus Therapeutics, Inc. | Methods for treating pompe disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3628326B1 (en) * | 2012-03-15 | 2024-02-28 | Oxyrane UK Limited | Methods and materials for treatment of pompe's disease |
| BR112017005810A2 (pt) * | 2014-09-30 | 2018-02-27 | Amicus Therapeutics Inc | alfa-glucosidase ácida altamente potente com carboidratos melhorados |
| KR102510941B1 (ko) * | 2015-12-30 | 2023-03-20 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 폼페병 치료용의 강화된 산 알파-글루코시다제 |
| DK3624831T3 (da) * | 2017-05-15 | 2023-06-26 | Amicus Therapeutics Inc | Rekombinant human sur alfa-glucosidase |
-
2022
- 2022-02-11 JP JP2023548587A patent/JP2024506346A/ja active Pending
- 2022-02-11 AU AU2022218792A patent/AU2022218792A1/en active Pending
- 2022-02-11 WO PCT/US2022/016124 patent/WO2022174037A1/en active Application Filing
- 2022-02-11 CA CA3207917A patent/CA3207917A1/en active Pending
- 2022-02-11 EP EP22753411.2A patent/EP4291225A1/en active Pending
- 2022-02-11 TW TW111105104A patent/TW202245830A/zh unknown
- 2022-02-11 BR BR112023016212A patent/BR112023016212A2/pt unknown
- 2022-02-11 KR KR1020237031038A patent/KR20230155622A/ko unknown
- 2022-02-11 IL IL305103A patent/IL305103A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230155622A (ko) | 2023-11-10 |
| AU2022218792A1 (en) | 2023-08-24 |
| WO2022174037A1 (en) | 2022-08-18 |
| TW202245830A (zh) | 2022-12-01 |
| EP4291225A1 (en) | 2023-12-20 |
| CA3207917A1 (en) | 2022-08-18 |
| JP2024506346A (ja) | 2024-02-13 |
| IL305103A (en) | 2023-10-01 |
| WO2022174037A9 (en) | 2023-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Koo et al. | Essential role of mesolimbic brain-derived neurotrophic factor in chronic social stress–induced depressive behaviors | |
| Li et al. | Tranexamic acid ameliorates rosacea symptoms through regulating immune response and angiogenesis | |
| ES2329232T3 (es) | Tratamiento de trastornos y afecciones neuromusculares con un serotipo botulinico diferente. | |
| ES2289591T3 (es) | Terapia con toxina botulinica para enfermedades de la piel. | |
| BR112023016212A2 (pt) | Alfa-glucosidase ácida humana recombinante e usos da mesma | |
| BR112022013746A2 (pt) | Formulação aquosa de cagrilintida, formulação aquosa de semaglutida, dispositivo médico, e, combinação de dose fixa | |
| CO2022002638A2 (es) | Métodos para tratar la enfermedad de fabry en pacientes que tienen una mutación en el gen gla | |
| BRPI0515070A2 (pt) | sistema de entrega de medicamento auto-emulsificante de butilftalida, sua preparação e método de aplicação | |
| BR112023016678A2 (pt) | Inibidores de tyk2 e usos dos mesmos | |
| JP2022191409A (ja) | 自律神経障害の治療 | |
| CL2022002423A1 (es) | Métodos para tratar la enfermedad de fabry | |
| BR112023001121A2 (pt) | Cepa c de prevotella histicola como uma terapia oral para doenças inflamatórias | |
| Alterman et al. | Functional and proteomic analysis of submandibular saliva in rats exposed to chronic stress by immobilization or constant light | |
| BR112022018480A2 (pt) | Moduladores de nlrp3 | |
| KR101870239B1 (ko) | D-갈락토오스를 포함하는 쿼럼센싱 저해제 | |
| ES2374619T3 (es) | Uso de hialuronidasa para la profilaxis y el tratamiento de enfermedades cardiovasculares. | |
| KR20130106557A (ko) | 보툴리눔 에이형 독소의 액상제품 | |
| US11707510B2 (en) | Nucleic acid-based botulinum neurotoxin for therapeutic use | |
| BR112022027124A2 (pt) | Formulações para promover a hidratação e métodos de uso das mesmas | |
| BR112022014119A2 (pt) | Administração oral de peptídeos | |
| FR3109523B1 (fr) | Nouveaux composés chaperons pharmacologiques de l’alpha-glucosidase acide humaine et leur utilisation thérapeutique | |
| Carrër et al. | Occurrence of an SME-2-producing Serratia marcescens isolate in Canada | |
| AR124854A1 (es) | a-GLUCOSIDASA ÁCIDA HUMANA RECOMBINANTE Y SUS USOS | |
| BR112023002900A2 (pt) | Peptídeo para aplicações terapêuticas no campo dermatológico | |
| BR112022021635A2 (pt) | Distrofinas miniaturizadas tendo domínios de fusão de espectrina e usos das mesmas |